Accurate staging of pancreatic neuroendocrine tumors (PNET) is critical for clinical success. Recent PNET imaging guidelines from the American College of Radiology (ACR) provide a roadmap for evaluating disease extent. These evidence-based recommendations help clinicians choose between various modalities like CT, MRI, and PET scans. Consequently, optimizing imaging protocols ensures better management for patients with both localized and metastatic disease.

Utilizing PNET Imaging Guidelines for Local Staging

Contrast-enhanced CT typically offers the best initial evaluation for most patients. It helps clinicians assess tumor size, locoregional extent, and vascular involvement. Furthermore, multiphasic protocols provide detailed information about tumor hypervascularity. Radiologists also prefer MRI for specific scenarios, particularly when evaluating the liver. Specifically, MRI with hepatobiliary contrast agents and diffusion-weighted imaging improves the detection of small liver metastases. Additionally, this modality characterizes liver-dominant disease more accurately than standard CT scans.

Role of Functional Imaging in Metastatic Disease

For advanced staging, DOTATATE PET/CT serves as a powerful tool. Guidelines suggest its use for staging and treatment planning in patients with known or suspected metastatic spread. However, clinicians reserve FDG-PET/CT for high-grade tumors that lack somatostatin receptor expression. Moreover, the ACR updates these criteria annually through systematic literature analysis. Expert panels adapt methodology principles like GRADE to evaluate clinical evidence carefully. In instances where literature is limited, expert consensus serves as the primary evidentiary source. Ultimately, following these standardized protocols leads to optimized patient outcomes.

Frequently Asked Questions

What are the primary imaging modalities for PNET staging?

Clinicians typically use contrast-enhanced CT and MRI as first-line tools for local staging and assessing vascular involvement. MRI with hepatobiliary contrast agents is particularly effective for evaluating liver metastases.

When should clinicians use DOTATATE PET/CT for PNET?

Current PNET imaging guidelines recommend DOTATATE PET/CT for staging and treatment planning in patients with suspected or confirmed metastatic disease, as it targets somatostatin receptors.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. undefined undefined et al. ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors. J Am Coll Radiol. 2026 Mar 13. doi: undefined. PMID: 41823937.

2. Kamel I, et al. ACR Appropriateness Criteria® Staging and Follow-up of Pancreatic Neuroendocrine Tumors. Journal of the American College of Radiology. 2025;22(11S):S494-S508.

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Islet Cell Tumors. Version 1.2024.